Search

Your search keyword '"Carcereny, E"' showing total 48 results
Start Over Author "Carcereny, E" Database Complementary Index
48 results on '"Carcereny, E"'

1. EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Author

de Castro, J., Cobo Dols, M., Dómine Gómez, M., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Ortega Granados, A.L., Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and García Campelo, R.

Published
2024
Full Text
View/download PDF

2. EP.01A.05 Analysis of Diagnostic Delay and Its Impact on Survival in Lung Cancer Cases. Results from the Spanish Thoracic Tumor Registry.

Author

Candal-Pedreira, C., Ruano-Ravina, A., Calvo de Juan, V., Cobo, M., Trigo, J.M., Rodríguez-Abreu, D., Estival, A., Carcereny, E., Cucurull, M., López Castro, R., Medina, A., García Campelo, R., Cordeiro González, P., Sánchez-Gastaldo, A., Bosch-Barrera, J., Massutí, B., Dómine, M., Camps, C., Ortega, A.L., and Provencio, M.

Published
2024
Full Text
View/download PDF

3. P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study.

Author

García-Campelo, R., Dómine Gómez, M., de Castro, J., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Granados, A.L. Ortega, Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and Cobo Dols, M.

Published
2024
Full Text
View/download PDF

5. EP.06G.20 Advanced Squamous Cell Lung Carcinoma in Never Smokers: A Different Entity? Analysis from the Thoracic Tumor Registry in Spain (RTT).

Author

Blanco, M., Collazo-Lorduy, A., Cobo, M., Calvo, V., Martínez- Cutillas, M., Cantero, A., Rodríguez-Abreu, D., Carcereny, E., Bosch-Barrera, J., García Campelo, M.R., López Castro, R., Bernabé, R., del Barco, E., Ortega, A.L., Sánchez, A., Aparisi-Aparisi, F., Vázquez, S., Guirado, M., Casal, J., and Medina, K.

Published
2024
Full Text
View/download PDF

6. EP.13D.09 Characteristics and Survival in Never-Smoking Small Cell Lung Cancer Cases an Analysis from the Thoracic Tumor Registry.

Author

Candal-Pedreira, C., Ruano-Ravina, A., Calvo de Juan, V., Cobo, M., Trigo, J.M., Rodríguez-Abreu, D., Estival, A., Carcereny, E., Cucurull, M., López Castro, R., Medina, A., García Campelo, R., Cordeiro González, P., Sánchez-Gastaldo, A., Bosch-Barrera, J., Massutí, B., Dómine, M., Camps, C., Ortega, A.L., and Provencio, M.

Published
2024
Full Text
View/download PDF

9. P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC.

Author

Dómine Gómez, M., Cobo Dols, M., de Castro, J., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem Tarruella, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Ortega Granados, A.L., Guillot Morales, M., Massuti Sureda, B., Vilà, L., Blasco Cordellat, A., Fajardo, C.A., Crama, L., Lerones, N., and García Campelo, R.

Published
2023
Full Text
View/download PDF

10. Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.

Author

Panciroli, C., Lucente, G., Vidal, L., Carcereny, E., Quiroga, V., Pardo, J. C., Romeo, M., Estival, A., Manzano, J. L., Pardo, B., Velarde, J. M., Esteve, A. M., Lopez, D., Mañes, A., Tuset, V., Villà, S., and Quintero, C. B.

Abstract

Purpose: We performed a cross-sectional study of neurocognitive function in non-brain cancer patients treated with long-term bevacizumab. Methods/patients: From 2015 to 2017, we included patients with different types of cancer treated with bevacizumab with or without chemotherapy (BEV; N = 20) or only chemotherapy (ChT; N = 19) for at least 34 weeks, patients who received non-brain radiotherapy (RxT; N = 19), and healthy controls (HC; N = 19) were assessed once at week 34 of treatment (BEV and ChT) or at completion of radiotherapy. Neurocognition was evaluated with the Hopkins Verbal Learning Test-Revised (HVLT-R) total and delayed recall, the Trail Making Test A and B, and the Controlled Oral Word Association Test in the four groups. Non-parametric tests were used to assess differences between groups. Results: The BEV, ChT, and RxT groups scored significantly lower than the HC group on all tests and especially on the HVLT-R total recall. In no case were the mean scores of the BEV group significantly lower than those of the ChT or RxT groups. Conclusions: Neurocognitive impairment was seen even in patients treated with local non-brain radiotherapy. Treatment with bevacizumab for a long period of time does not seem to worsen neurocognitive function to a greater extent than chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

11. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.

Author

Provencio, M., Carcereny, E., and Artal, Á.

Abstract

Introduction: Many methods used to assess the effectiveness of immune checkpoint (programmed death-ligand 1 or cytotoxic T-lymphocyte-associated protein 4) inhibitors for non-small cell lung cancer (NSCLC) are insufficient, as the therapeutic benefit of these agents is often underestimated. Consequently, immune-related evaluation criteria have been developed to better reflect their efficacy. The aim of this consensus was to obtain the opinion of lung cancer experts on the adequacy of immune-response criteria for evaluating the efficacy of these treatments. Methods: Through two rounds of a modified Delphi consensus, 18 Spanish lung cancer experts participated in a 15-item questionnaire regarding the use of immunotherapies for NSCLC and the assessment criteria used to evaluate their effectiveness. Results: Consensus was achieved on 80% of the items in the questionnaire. The panelists agreed that although the Response Evaluation Criteria in Solid Tumors (RECIST) are standard for the evaluation of solid tumors, immune-related response criteria would be useful for measuring the efficacy of immunotherapy. In addition, they considered that an overall survival (OS) rate at 2–5 years is the most useful end point for assessing the benefit of immunotherapy, as clinical benefit may extend beyond the RECIST criteria-defined progression of disease. Conclusions: Although immune-related response criteria have been developed to better evaluate the efficacy of immunotherapy, their use has not been validated and is restricted to investigational applications. However, they may prove to be a useful tool for measuring the efficacy of immunotherapy agents in NSCLC, especially the OS rate at 2–5 years. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

12. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.

Author

Corral, J., Majem, M., Rodríguez-Abreu, D., Carcereny, E., Cortes, Á. A., Llorente, M., López Picazo, J. M., García, Y., Domine, M., and López Criado, M P.

Abstract

Purpose: Both nintedanib/docetaxel and anti‐PD‐1/PD‐L1 immunotherapies have demonstrated efficacy as second‐line treatment of patients with advanced lung adenocarcinoma. This is the first report on the efficacy of the nintedanib/docetaxel combination following first‐line platinum‐based chemotherapy and subsequent immunotherapy in a real-world setting. Methods/patients: From May 2014 to December 2015, 390 patients in 108 Spanish centres enrolled in the nintedanib named patient use program. Inclusion criteria were advanced lung adenocarcinoma with progressive disease following at least one line of platinum‐based doublet chemotherapy. The objective was to evaluate the efficacy of the nintedanib/docetaxel combination in patients who also received immunotherapy. Results: Eleven patients met the inclusion criteria; with a median age of 67 years. PD‐L1 expression was positive in six patients. Median progression‐free survival (PFS) of first‐line platinum‐based chemotherapy was 3.3 months (95% CI 1.9–4.6). Second‐line immunotherapy was pembrolizumab (36.5%), atezolizumab (36.5%) or nivolumab (27%). Median PFS of second‐line immunotherapy was 2.3 months (95% CI 0–6.1). The overall response rate (ORR) to second‐line immunotherapy was 18% with a disease‐control rate (DCR) of 45%. Median PFS of nintedanib/docetaxel was 3.2 months (95% CI 1.9–4.5). Best response was partial response in four patients (36%), stable disease in five patients (46%), and progressive disease in two patients (18%), for an ORR of 36% and a DCR of 82%. Conclusion: Our experience suggests an encouraging efficacy of nintedanib/docetaxel in patients with adenocarcinoma NSCLC pretreated with platinum‐based doublet chemotherapy and immunotherapy, reinforcing the importance of an optimal therapeutic sequence for managing advanced lung adenocarcinoma. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

13. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).

Author

Majem, M., Juan, O., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García-Campelo, R., García, Y., Guirado, M., and Provencio, M.

Abstract

Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment attains greater value. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

15. P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study.

Author

García-Campelo, R., Dómine Gómez, M., de Castro, J., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem Tarruella, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Ortega Granados, A.L., Guillot Morales, M., Massuti Sureda, B., Vilà, L., Blasco Cordellat, A., Fajardo, C.A., Crama, L., Lerones, N., and Cobo Dols, M.

Published
2023
Full Text
View/download PDF

17. P1.01-04 Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients.

Author

Candal-Pedreira, C., Ruano-Ravina, A., Calvo de Juan, V., Cobo, M., Trigo, J.M., Carcereny, E., Cucurull, M., López Castro, R., Solís García, E., Sánchez-Gastaldo, A., Massutí, B., Rodríguez-Abreu, D., Estival, A., Guirado Risueño, M., Rey-Brandariz, J., Pamiés Ramón, M., García Campelo, R., Alonso-Jáudenes, G., Camps, C., and del Barco Morillo, E.

Published
2023
Full Text
View/download PDF

21. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

Author

Remon, J., Isla, D., Garrido, P., Castro, J., Majem, M., Viñolas, N., Artal, A., Carcereny, E., García-Campelo, M., Lianes, P., Provencio, M., Juan, O., Diz, P., Blanco, R., Lopez-Castro, R., Maestu, I., Vadell, C., and Felip, E.

Abstract

Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor ( EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

28. 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results.

Author

Aix, S. Ponce, Juan-Vidal, O., Carcereny, E., Trigo, J.M., Provencio, M., Greillier, L., Navarro, A., Bennouna, J., Santoro, A., Berardi, R., Besse, B., Gonzalez, H., de Alvaro, J., Parra-Palau, J.L., Sánchez-Pérez, T., Aronchik, I., Filvaroff, E., Lamba, M., Nikolova, Z., and Paz-Ares, L.

Published
2021
Full Text
View/download PDF

30. Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies.

Author

Miralles, C., Orea, M., España, P., Provencio, M., Sánchez, A., Cantos, B., Cubedo, R., Carcereny, E., Bonilla, F., and Gea, T.

Abstract

Background:Cancer antigen (CA) 125 tumor-associated antigen is a high molecular glycoprotein used for follow-up of epithelial ovarian cancer. The test is often requested as a differential diagnosis in patients with pleural or peritoneal fluid. This study analyzes the prevalence of CA-125 increases in a population of patients attending a general hospital and discusses the possible clinical implications of increased levels. Methods:On 4 different days, 380 CA-125 assays were performed in randomly selected patients attending our hospital. Serum CA-125 was measured with a commercial enzyme immunoassay, and clinical records were reviewed for assessment of clinical parameters. Results:Sixty-one patients (16%) had increased CA-125. The pathologies of these patients were heart failure in 9 (14.7%), lung disease 11 (18%), hepatic cirrhosis in 7 (11.4%), malignant tumors in 9 (14.7%), intra-abdominal nonhepatic disease in 6 (10%), previous surgery in 17 (27.8%), and miscellaneous in 2 (3%). Effusions were seen in 34 patients (55.7%). Conclusions:Our data confirm the variety of benign and malignant pathologies coursing with increased CA-125. Cardiovascular and chronic liver disease were the most frequent diagnoses in patients with increased CA-125; this supports the opinion that CA-125 lacks utility as a marker for malignancy. CA-125 could have a role in the follow-up of cardiovascular, hepatic, and tumoral diseases with serosal involvement. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

33. P2.10-02 Smoking Habit in Lung Cancer in Spain.

Author

Carcereny, E., Franco, F., Rodriguez-Abreu, D., Castro, R. Lopez, De Las Penas, R., Guirado, M., Camps, C., Bosch-Barrera, J., Campelo, R. Garcia, Ortega, A.L., Gonzalez-Larriba, J.L., Huidobro, G., Domine, M., Massuti, B., Sala, M.a., Bernabe, R., Oramas, J., Del Barco, E., De Castro Carpeno, J., and Padilla, A.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results